Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 325

Sort by

Sort Order Select

Journal Articles

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede, Ulrich J. Sachs, Andreas Czwalinna, Sonja Werwitzke, Rolf Bikker, Joachim K. Krauss, Frank Donnerstag, Karin Weißenborn, Günter Höglinger, Benjamin Maasoumy, Heiner Wedemeyer, Arnold Ganser

Blood (2021) 138 (4): 350–353.

https://doi.org/10.1182/blood.2021011958

Published: 2021

Includes: Supplemental data

Journal Articles

Eculizumab and aHUS: to stop or not

Robert A. Brodsky

Blood (2021) 137 (18): 2419–2420.

https://doi.org/10.1182/blood.2020010234

Published: 2021

Journal Articles

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Blood (2021) 137 (18): 2438–2449.

https://doi.org/10.1182/blood.2020009280

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky

Blood (2021) 137 (10): 1304–1309.

https://doi.org/10.1182/blood.2019003812

Published: 2021

Journal Articles

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab

Sonata Jodele, Christopher E. Dandoy, Adam Lane, Benjamin L. Laskin, Ashley Teusink-Cross, Kasiani C. Myers, Gregory Wallace, Adam Nelson, Jack Bleesing, Ranjit S. Chima, Russel Hirsch, Thomas D. Ryan, Stefanie Benoit, Kana Mizuno, Mikako Warren, Stella M. Davies

Blood (2020) 135 (13): 1049–1057.

https://doi.org/10.1182/blood.2019004218

Published: 2020

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Blood (2020) 135 (12): 912–920.

https://doi.org/10.1182/blood.2019003399

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, MD, Min Ji Jeon, Eun Sang Yu, MD, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD PhD, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park

Blood (2019) 134 (Supplement_1): 2227.

https://doi.org/10.1182/blood-2019-125269

Published: 2019

Journal Articles

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Kishor Devalaraja-Narashimha, PhD DVM, Yan G Ni, PhD, Cong Huang, Ming-Dauh Wang, PhD, Umesh Chaudhari, MD, Srinivasa Prasad, PhD, Olivier Harari, MD PhD, Andrew J Rankin, PhD, Lori Morton, PhD, Jonathan Weyne, MD

Blood (2019) 134 (Supplement_1): 2278.

https://doi.org/10.1182/blood-2019-129865

Published: 2019

Journal Articles

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Matheus Vescovi, MD PhD, Iara Baldim Rabelo Gomes, MD PhD, Ismael Dale Cotrim Guerreiro da Silva, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2229.

https://doi.org/10.1182/blood-2019-126241

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Aleksandr Kulagin, Vadim Ptushkin, MD PhD Professor, Elena Lukina, MD PhD Professor, Elena Gapchenko, MD, Oksana Markova, MD MSc, Eugene Zuev, MD, Dmitry Kudlay, MD PhD Professor

Blood (2019) 134 (Supplement_1): 3748.

https://doi.org/10.1182/blood-2019-125693

Published: 2019

Journal Articles

Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients

Alexandre Sostelly, M.Eng., PhD, Simon Buatois, Antoine Soubret, Erica Winter, PharmD, Barbara Klughammer, PhD, Joy C. Hsu, Gregor Jordan, Christoph Bucher, MD, Jean-Eric Charoin, Keisuke Gotanda, Kenji Shinomiya, Zsolt Nagy, MD PhD, Jens P. Panse, Sung-Soo Yoon, MD PhD, Régis Peffault de Latour, MD PhD, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD

Blood (2019) 134 (Supplement_1): 3745.

https://doi.org/10.1182/blood-2019-124258

Published: 2019

Journal Articles

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Alexandre Sostelly, M.Eng., PhD, Antoine Soubret, Christoph Bucher, MD, Simon Buatois, Jean-Eric Charoin, Gregor Jordan, Barbara Klughammer, PhD, Andreas Dieckmann, Taku Fukuzawa, PhD, Keisuke Gotanda, Kenji Shinomiya, Sung-Soo Yoon, MD PhD, Jens P. Panse, Junichi Nishimura, MD PhD, Alexander Röth, MD PhD, Zsolt Nagy, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 1227.

https://doi.org/10.1182/blood-2019-126911

Published: 2019

Journal Articles

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Magali Le Garff-Tavernier, Agathe Pruvot Debliquis, PharmD, Thomas Boyer, MD, Jean-Philippe Vial, MD, Véronique Harrivel, MD, Anne-Catherine Lhoumeau, PhD PharmD, Marie-Christine Jacob, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD, Bernard Drenou, MD PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 1218.

https://doi.org/10.1182/blood-2019-123415

Published: 2019

Journal Articles

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, MD, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, MD PhD, Eric Rondeau, Marie Scully, Stephan Ortiz, RPh, PhD

Blood (2019) 134 (Supplement_1): 1099.

https://doi.org/10.1182/blood-2019-122421

Published: 2019

Journal Articles

Platelet Function in Paroxysmal Nocturnal Haemoglobinuria

Fathima Mohiyaddin Ayyalil, MBBS, FRACP,FRCPA, Samantha J Montague, BSc, PhD, Sarah Hicks, Amandeep Kaur, PhD, Anila Jahangiri, Nalini Pati, MBBS,FRACP,FRCPA, DCH, MD DNB, Philip Crispin, MBBS, FRACP, FRCPA, Yujie Zheng, Xu Tienan, Lucy Coupland, PhDBSc,RN, Woei Ming Lee, James D'Rozario, MBBS, FRACP, FRCPA, Elizabeth E. Gardiner, PhD

Blood (2019) 134 (Supplement_1): 4884.

https://doi.org/10.1182/blood-2019-130291

Published: 2019

Journal Articles

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

David J. Araten, MD, H. Leon Pachter, Robert J Dring, Elliot Newman, Steven M Cohen

Blood (2019) 134 (Supplement_1): 4795.

https://doi.org/10.1182/blood-2019-124571

Published: 2019

Journal Articles

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Sarah A Lau-Braunhut, MD, Hannah Stone, Griffin Collins, MD, Sigbjørn Berentsen, MD PhD, Matt Zinter, MD, Benjamin Braun, MD PhD

Blood (2019) 134 (Supplement_1): 4798.

https://doi.org/10.1182/blood-2019-126365

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Eculizumab and aHUS: to stop or not

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

How I treat paroxysmal nocturnal hemoglobinuria

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab

A complementary new drug for PNH

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological Data

Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients

Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Platelet Function in Paroxysmal Nocturnal Haemoglobinuria

Symptomatic Bilirubin Gallstones in Patients with PNH Treated with Eculizumab

Paroxysmal Cold Hemoglobinuria Successfully Treated with Complement Inhibition

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only